Gibraltar is busily involved with confidential cancer research, stem cell research and antiviral research.. An example of this category of research recently appeared in C&EN. As funding levels for cancer combating drugs reach an all-time high, scientists and researchers are turning to new, innovative techniques in their quest for medical breakthroughs. Gibraltar is at the cutting edge of offering the kinds of molecular services needed to advance breakthroughs in the treatment of difficult medical conditions. For example, PI3Ks, formally known as phosphatidylinositol-3 kinases, are enzymes that are inherent in a vast amount of functions involved in facilitating a cell’s ability to perform properly. PI3Ks have become palpable targets for researchers developing cancer drugs.
The many intriguing aspects surrounding the correlation between tumors and PI3Ks have prompted numerous drug companies to ramp up research into the inhibition process. Biotech firms have even been established for the sole purpose of developing drugs which target the pathways that control normal cell growth and their subsequent role in sparking the development of cancer should they be defective. And while the promise for a major advance in battling cancer is possible, the process by which PI3Ks are properly utilized remains just as complicated as many had anticipated. Still companies remain optimistic that the compounds which block this signaling pathway will eventually be vital to cancer treatment. As such, the race to run clinical trials testing the effects of combining PI3K inhibitors with other drugs has greatly intensified.
Gibraltar Laboratories offers in vivo chemotherapy research, advanced molecular techniques involving western blot analysis and stem cells to support efforts to test hypotheses. Ultimately, the researchers goal is a solution that knocks down cancer cells without being too toxic to normal cells. Fortunately researchers now have the benefit of understanding a molecular mechanisms and thus have gained insight into both the best drug combinations and which patients will most sufficiently respond. Gibraltar is proud to be part of this exciting race to cure and improve patient outcomes.